HomeCompareTUFBY vs JNJ

TUFBY vs JNJ: Dividend Comparison 2026

TUFBY yields 6.33% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TUFBY wins by $60.6K in total portfolio value
10 years
TUFBY
TUFBY
● Live price
6.33%
Share price
$6.95
Annual div
$0.44
5Y div CAGR
25.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$90.9K
Annual income
$21,484.31
Full TUFBY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — TUFBY vs JNJ

📍 TUFBY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTUFBYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TUFBY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TUFBY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TUFBY
Annual income on $10K today (after 15% tax)
$538.13/yr
After 10yr DRIP, annual income (after tax)
$18,261.66/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, TUFBY beats the other by $14,275.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TUFBY + JNJ for your $10,000?

TUFBY: 50%JNJ: 50%
100% JNJ50/50100% TUFBY
Portfolio after 10yr
$60.6K
Annual income
$13,086.85/yr
Blended yield
21.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TUFBY
No analyst data
Altman Z
1.7
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TUFBY buys
0
JNJ buys
0
No recent congressional trades found for TUFBY or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTUFBYJNJ
Forward yield6.33%2.13%
Annual dividend / share$0.44$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR25.4%28%
Portfolio after 10y$90.9K$30.3K
Annual income after 10y$21,484.31$4,689.40
Total dividends collected$62.0K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TUFBY vs JNJ ($10,000, DRIP)

YearTUFBY PortfolioTUFBY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,494$793.90$10,592$272.30+$902.00TUFBY
2$13,368$1,069.42$11,289$357.73+$2.1KTUFBY
3$15,761$1,457.66$12,123$472.89+$3.6KTUFBY
4$18,879$2,014.18$13,141$629.86+$5.7KTUFBY
5$23,028$2,827.44$14,408$846.81+$8.6KTUFBY
6$28,682$4,041.90$16,021$1,151.60+$12.7KTUFBY
7$36,589$5,899.98$18,122$1,588.22+$18.5KTUFBY
8$47,971$8,820.95$20,930$2,228.20+$27.0KTUFBY
9$64,883$13,553.72$24,792$3,191.91+$40.1KTUFBY
10$90,909$21,484.31$30,274$4,689.40+$60.6KTUFBY

TUFBY vs JNJ: Complete Analysis 2026

TUFBYStock

Thai Union Group Public Company Limited, together with its subsidiaries, manufactures and sells frozen, chilled, and canned seafood in Thailand and internationally. The company operates through three segments: Ambient Seafood; Frozen and Chilled Seafood and Related Businesses; and Pet food, Value-Added and Other Businesses. It offers ambient seafood products, including tuna, sardines, salmon, mackerel, herring, and salmon for retail and wholesale customers; frozen and chilled seafood, such as shrimp, lobster, and crab sold directly to restaurants, hotels, and caterers; ready-to-cook or ready-to-serve products, as well as bakery treats; marine ingredients for use in consumer goods, such as infant formula, cosmetics, dietary supplements, and clinical nutrition; and pet care products comprising surimi-based fish snacks, canned cod liver, and wet seafood-based cat and dog foods. The company provides its products under the Chicken of the Sea, Genova, John West, Petit Navire, Parmentier, King Oscar, Mareblu, Rügen Fisch, Sealect, Fisho, QFresh, Monori, Bellotta and Marvo, Zeavita, OMG Meat, Red lobster, Interpharma- ZEAvita, and Food and Beverage United brands. It also manufactures and distributes canned tuna and seafood, pet food, frozen shrimps, animal feeds, frozen foods and aquatic animals, ingredients product, and smoked salmon. In addition, the company offers printing manufacturing, export and import, training and management, e-commerce, consultancy, technical, and property rental services. Further, it is involved in the packaging, tuna oil refinery, shrimp farming, and shrimp breeding and hatchery businesses. The company was formerly known as Thai Union Frozen Products Public Company Limited and changed its name to Thai Union Group Public Company Limited in September 2015. Thai Union Group Public Company Limited was founded in 1977 and is headquartered in Mueang Samut Sakhon, Thailand.

Full TUFBY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this TUFBY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TUFBY vs SCHDTUFBY vs JEPITUFBY vs OTUFBY vs KOTUFBY vs MAINTUFBY vs ABBVTUFBY vs MRKTUFBY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.